The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
It will be a dry night with clear spells for all of us, but the south-easterly wind will increase, becoming rather windy by morning.
Hundreds of campaigners are marching through the streets of Cardiff calling for the city's grassroots music venues to be protected.
People in Wales living with cancer face losing over £500 a month in income after diagnosis, according to Macmillan Wales.